Moreover, most research on the TIME in HER2-positive BC has so far focused on the prognostic effect of stromal tumor infiltrating lymphocytes (sTIL)7,8, and the predictive value for response to neo-adjuvant chemotherapy or HER2-targeted therapy3,9–12. Here, ERBB2 is linked to breast cancer.